A mother with terminal illness expresses sorrow over losing friends prematurely due to the Government’s delay in approving a life-prolonging medication. Sophie Blake, 53, residing in Brighton, faces incurable stage four breast cancer.

Sophie laments the denial of the revolutionary drug Enhertu, which could have offered vital additional time to her friends, including a mother with a young son. Despite the drug being accessible to women globally, it remains inaccessible to women with HER2-low stage 4 secondary breast cancer in England, Wales, and Northern Ireland. The drug, capable of providing six more months of life, has been declined by the NHS.

“I have witnessed many friends in need of this treatment,” Sophie expressed. “The loss of another dear friend today, a mother who could have had more time with her children, is truly heartbreaking. Lives are being cut short due to this decision.”

Diagnosed in May 2022 with secondary breast cancer affecting various organs, including her liver, lungs, and lymph nodes, Sophie currently maintains her condition with targeted cancer therapy. However, she lives in constant fear of the cancer’s return, describing it as a ticking time bomb.

Expressing the urgent need for the drug, Sophie highlights the lack of hope for herself and other women in the region, contrasting with countries worldwide that have access to it. The rejection of Enhertu by the National Institute for Health and Care Excellence (NICE) in 2024 was based on cost-effectiveness, despite the drug’s potential benefits.

Sophie emphasizes the detrimental impact on women’s lives, pointing out the limited funding and access to advanced treatments. She underscores the urgency for change in the current healthcare system to prevent further loss of lives among women battling metastatic breast cancer.

The struggle for access to treatments and the fight for survival dominate the lives of women with secondary breast cancer, who often feel neglected and expendable in the healthcare system. The time that should be spent creating memories and living a fulfilling life is consumed by battles for proper care and treatments.

NICE’s failure to recommend Enhertu due to pricing disagreements between companies and NHS England has left approximately 1000 women in England and Wales without access to the advanced breast cancer drug. The importance of fair pricing to ensure timely access to essential medications for patients is emphasized by NICE, urging companies to cooperate for the benefit of those in need.